

Cover Story
After a courtroom victory against Amgen Inc. this summer, the last of the obstacles was removed for the first biosimilar agent—a white blood cell growth factor—to enter the U.S. market.
By Matthew Bin Han Ong
By Matthew Bin Han Ong
In Brief
Drugs & Targets


Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- NCI slated to get a $9 million raise as Trump’s budget proposes about 10% cut for NIH
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- Trump imposes up to 100% tariff on some brand name pharmaceutical companies
- Michael Bishop, Nobel-winning cancer researcher, dies at 90
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case











